About Us

ShunTech Biodevices aims to provide solutions to the clinical
concerns of current eye stents through our advanced
technology. We focus on biodevices of novel and new
materials that are neither metal nor polymers. Inspired by
the efforts of Dr. Larry Hench in the development of
bioactive glass in 1969, we invented the Bioresorbable
Glaucoma Scaffold (BGS) without indications of
inflammatory response, scar tissue formation, biofilm or
post-dissolution cytotoxic effects. Unlike devices composed
of PLGA, our Bioresorbable Glaucoma Scaffolds (BGS) based
on a dissolvable biosilicate material do not have encrusting
erosions. The Bioresorbable Glaucoma Scaffold (BGS)
mitigates infection, relieves chronic inflammation and
promotes wound healing. With current MIG implants
presenting many clinical challenges, ShunTech BGS strives to
prevent implant rejection, enhance wound healing and act
as a drug delivery system.